Paper Details

  1. Home
  2. Paper Details

Eflornithine versus cotrimoxazole in the treatment of Pneumocystis carinii pneumonia in AIDS patients.

Author: DaviesS, GazzardB G, HardingI, SmithD E, SmithsonJ

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Cotrimoxazole is more effective than eflornithine for the treatment of first-episode Pneumocystis carinii pneumonia. Eflornithine had activity against the organism, but more patients discontinued treatment due to therapy failure. Cotrimoxazole was associated with more serious drug-related side effects.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: To compare cotrimoxazole and eflornithine as primary treatment for first-episode Pneumocystis carinii pneumonia (PCP). DESIGN: Prospective open-labelled study. METHODS: Patients were randomized to eflornithine (400 mg/kg daily, as a continuous intravenous infusion) or cotrimoxazole (3....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00002030-199212000-00011

データ提供：米国国立医学図書館（NLM）

Eflornithine vs. Cotrimoxazole: A Battle in the Desert of PCP

Pneumocystis carinii pneumonia (PCP) is a serious opportunistic infection that can be life-threatening in individuals with weakened immune systems. This prospective, open-label study compares two medications, eflornithine and cotrimoxazole, for the treatment of first-episode PCP in AIDS patients. The results indicate that cotrimoxazole is more effective than eflornithine, though both have limitations in terms of treatment success and side effects. This is like navigating a treacherous desert, where two paths are available, but each presents its own challenges and risks.

The Battle for Survival: Eflornithine vs. Cotrimoxazole

The study reveals that cotrimoxazole is more effective than eflornithine in treating first-episode PCP in AIDS patients. This is like discovering that one path through the desert leads to a lush oasis, while the other leads to a barren wasteland. The findings highlight the need for careful consideration of treatment options and the importance of monitoring for potential side effects. This is like having a trusty camel caravan and a skilled guide to navigate the challenges of PCP treatment.

Navigating the Desert of Opportunistic Infections

This study provides valuable insights into the treatment of PCP, highlighting the need for effective medications and careful monitoring for adverse events. This is like having a compass and a map to guide us safely through the challenges of opportunistic infections in individuals with weakened immune systems. The authors emphasize the need for further research to develop more effective and safer treatments for PCP, a quest that is like searching for a hidden oasis in the vast desert of infectious disease research.

Dr.Camel's Conclusion

This study demonstrates the superiority of cotrimoxazole over eflornithine in treating first-episode PCP in AIDS patients. This is like discovering that one path through the desert leads to a lush oasis, while the other leads to a barren wasteland. The findings highlight the importance of choosing the right treatment for each patient and being prepared for the challenges of treating opportunistic infections.

Date :
  1. Date Completed 1993-03-05
  2. Date Revised 2019-07-18
Further Info :

Pubmed ID

1492932

DOI: Digital Object Identifier

10.1097/00002030-199212000-00011

Related Literature

Article Analysis
・Side Effects of eflornithine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.